NO309926B1 - Farmasøytisk blanding egnet for nasal administrering, forbindelse og anvendelse derav - Google Patents

Farmasøytisk blanding egnet for nasal administrering, forbindelse og anvendelse derav Download PDF

Info

Publication number: NO309926B1
Authority: NO; Norway
Prior art keywords: androsta; dien; methyl; hydroxy; androst
Prior art date: 1993-06-15

Application number

NO955085A

Other languages

English (en)

Norwegian (no)

Other versions

NO955085L (no

NO955085D0 (no

Inventor

David L Berliner

Nathan William Adams

Clive L Jennings-White

Original Assignee

Pherin Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-15

Filing date

1995-12-14

Publication date

2001-04-23

1995-12-14 Application filed by Pherin Pharm Inc filed Critical Pherin Pharm Inc

1995-12-14 Publication of NO955085D0 publication Critical patent/NO955085D0/no

1996-02-14 Publication of NO955085L publication Critical patent/NO955085L/no

2001-04-23 Publication of NO309926B1 publication Critical patent/NO309926B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 40
239000008194 pharmaceutical composition Substances 0.000 title abstract description 6
150000003431 steroids Chemical class 0.000 claims abstract description 65
-1 Androstane steroid Chemical class 0.000 claims abstract description 46
230000002267 hypothalamic effect Effects 0.000 claims abstract description 16
239000003937 drug carrier Substances 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 85
HNDHDMOSWUAEAW-VMXHOPILSA-N androstadienone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC2=C1 HNDHDMOSWUAEAW-VMXHOPILSA-N 0.000 claims description 26
230000008859 change Effects 0.000 claims description 23
HNDHDMOSWUAEAW-UHFFFAOYSA-N (8alpha,9beta,10alpha,13alpha,14beta)-Androsta-4,6-dien-3-one Natural products O=C1CCC2(C)C3CCC(C)(C=CC4)C4C3CCC2=C1 HNDHDMOSWUAEAW-UHFFFAOYSA-N 0.000 claims description 22
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
125000004043 oxo group Chemical group O=* 0.000 claims description 16
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
125000000217 alkyl group Chemical group 0.000 claims description 13
239000001257 hydrogen Substances 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
125000003545 alkoxy group Chemical group 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
GOJSMZGIOCBZMX-UNTXSKPGSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-2,7,8,9,11,12,14,15-octahydro-1h-cyclopenta[a]phenanthrene-3,6-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC(=O)C2=C1 GOJSMZGIOCBZMX-UNTXSKPGSA-N 0.000 claims description 7
230000037424 autonomic function Effects 0.000 claims description 7
239000007788 liquid Substances 0.000 claims description 7
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 7
NYVFCEPOUVGTNP-UGCZWRCOSA-N (3r,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound O[C@@H]1CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC2=C1 NYVFCEPOUVGTNP-UGCZWRCOSA-N 0.000 claims description 6
VSVZWJKDKUJVBS-VMXHOPILSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3C=CC2=C1 VSVZWJKDKUJVBS-VMXHOPILSA-N 0.000 claims description 6
NGYDAURHEQWDMO-VMXHOPILSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC2=C1 NGYDAURHEQWDMO-VMXHOPILSA-N 0.000 claims description 6
MSEZLHAVPJYYIQ-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 MSEZLHAVPJYYIQ-VMXHOPILSA-N 0.000 claims description 6
QXEURENTQIAFIS-FSGKZVOOSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-17-methylidene-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CCC2=C1 QXEURENTQIAFIS-FSGKZVOOSA-N 0.000 claims description 6
CHJXZIUSUPUNBC-VPAKFMSCSA-N (8s,9s,10s,13r,14s)-10-(hydroxymethyl)-13-methyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(CO)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC2=C1 CHJXZIUSUPUNBC-VPAKFMSCSA-N 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
HZTZILUYYUBRRV-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 HZTZILUYYUBRRV-VMXHOPILSA-N 0.000 claims description 5
IQUXBKUKXDWZLA-VMXHOPILSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 IQUXBKUKXDWZLA-VMXHOPILSA-N 0.000 claims description 5
JPXLBSACCQTJJU-HVTWWXFQSA-N (8s,9s,10r,13s,14s)-3-methoxy-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1C[C@@H]2[C@](CCC(OC)=C3)(C)C3=CC[C@H]2[C@@H]2CCC[C@]21C JPXLBSACCQTJJU-HVTWWXFQSA-N 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
125000001424 substituent group Chemical group 0.000 claims description 5
125000004423 acyloxy group Chemical group 0.000 claims description 4
125000005041 acyloxyalkyl group Chemical group 0.000 claims description 4
125000005042 acyloxymethyl group Chemical group 0.000 claims description 4
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
125000004849 alkoxymethyl group Chemical group 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
CDCQHKMEOJJEBD-SIRBJWHBSA-N (3s,8s,9s,10r,13s,14s)-10,13-dimethyl-17-methylidene-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CC=C21 CDCQHKMEOJJEBD-SIRBJWHBSA-N 0.000 claims description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
IRLWRBCIMRVIJL-WKKSIBQESA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-17-methylidene-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,6-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CC(=O)C2=C1 IRLWRBCIMRVIJL-WKKSIBQESA-N 0.000 claims 5
XOVCYXHQJVVPTJ-UGCZWRCOSA-N (3R,8S,9S,10R,13R,14S)-10,13-dimethyl-6,7,8,9,11,12,14,15-octahydro-3H-cyclopenta[a]phenanthren-3-ol Chemical compound C[C@@]12C=CC[C@H]1[C@@H]1CCC3=C[C@@H](C=C[C@]3(C)[C@H]1CC2)O XOVCYXHQJVVPTJ-UGCZWRCOSA-N 0.000 claims 4
UPALZTGKKPGEBX-UGCZWRCOSA-N (3R,8S,9S,10R,13S,14S)-10,13-dimethyl-6,7,8,9,11,12,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-ol Chemical compound C[C@@]12CCC[C@H]1[C@@H]1CCC3=C[C@@H](C=C[C@]3(C)[C@H]1CC2)O UPALZTGKKPGEBX-UGCZWRCOSA-N 0.000 claims 4
JMCNUPJJRLUBQN-JZCOGDJRSA-N (3r,8s,9s,10r,13s,14s)-10,13-dimethyl-17-methylidene-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound O[C@@H]1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CCC2=C1 JMCNUPJJRLUBQN-JZCOGDJRSA-N 0.000 claims 4
LYFPAZBMEUSVNA-UGCZWRCOSA-N (3r,8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 LYFPAZBMEUSVNA-UGCZWRCOSA-N 0.000 claims 4
SWKKWQJKXGIFGE-UGCZWRCOSA-N (3r,8s,9s,10r,13s,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1CC2=C[C@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 SWKKWQJKXGIFGE-UGCZWRCOSA-N 0.000 claims 4
ASWJTSNORQOXAF-FTQUJXNBSA-N (6S,8S,9S,10R,13S,14S)-6-hydroxy-10,13-dimethyl-17-methylidene-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound C=C1[C@]2(C)[C@@H](CC1)[C@@H]1C[C@@H](C3=CC(CC[C@]3(C)[C@H]1CC2)=O)O ASWJTSNORQOXAF-FTQUJXNBSA-N 0.000 claims 4
ARYSJXDARDVLJA-VPAKFMSCSA-N (8s,9s,10s,13s,14s)-10-(hydroxymethyl)-13-methyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(CO)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 ARYSJXDARDVLJA-VPAKFMSCSA-N 0.000 claims 4
ONGIFLBAWWOZCE-WKWVNEEDSA-N (8s,9s,10s,13s,14s)-10-(hydroxymethyl)-13-methyl-17-methylidene-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(CO)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CCC2=C1 ONGIFLBAWWOZCE-WKWVNEEDSA-N 0.000 claims 4
CDCQHKMEOJJEBD-JZCOGDJRSA-N (3R,8S,9S,10R,13S,14S)-10,13-dimethyl-17-methylidene-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound C=C1[C@]2(C)[C@@H](CC1)[C@@H]1CC=C3C[C@@H](CC[C@]3(C)[C@H]1CC2)O CDCQHKMEOJJEBD-JZCOGDJRSA-N 0.000 claims 3
BAQLRGWZNMVLIB-FSGKZVOOSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-17-methylidene-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CCC2=C1 BAQLRGWZNMVLIB-FSGKZVOOSA-N 0.000 claims 3
AGHRVPJHGYJPGR-UNTXSKPGSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthrene-3,6-dione Chemical compound C1C(=O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 AGHRVPJHGYJPGR-UNTXSKPGSA-N 0.000 claims 3
WCMAEFVITFKHBM-FCMAGTKHSA-N (8s,9s,10r,13s,14s)-3-methoxy-10,13-dimethyl-17-methylidene-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene Chemical compound C1C[C@@H]2[C@](CCC(OC)=C3)(C)C3=CC[C@H]2[C@@H]2CCC(=C)[C@]21C WCMAEFVITFKHBM-FCMAGTKHSA-N 0.000 claims 3
TUNBJAMJFLUBAR-XNPNQNQESA-N (6S,8S,9S,10R,13S,14S)-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O[C@H]1C[C@H]2[C@@H]3CCC[C@@]3(C)CC[C@@H]2[C@]2(CCC(C=C12)=O)C TUNBJAMJFLUBAR-XNPNQNQESA-N 0.000 claims 2
FHGPDDJDYJYJQP-XNPNQNQESA-N (6s,8s,9s,10r,13r,14s)-6-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3C[C@H](O)C2=C1 FHGPDDJDYJYJQP-XNPNQNQESA-N 0.000 claims 2
CJEBYIFOGQBCCD-FSGKZVOOSA-N (8S,9S,10R,13S,14S)-10,13-dimethyl-17-methylidene-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene Chemical compound C=C1[C@]2(C)[C@@H](CC1)[C@@H]1CC=C3C=CCC[C@]3(C)[C@H]1CC2 CJEBYIFOGQBCCD-FSGKZVOOSA-N 0.000 claims 2
JTAYNEOHRXKDCK-FSGKZVOOSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-17-methylidene-2,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3C=CC2=C1 JTAYNEOHRXKDCK-FSGKZVOOSA-N 0.000 claims 2
JMCNUPJJRLUBQN-MQODNCJTSA-N (8s,9s,10r,13s,14s)-10,13-dimethyl-17-methylidene-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound OC1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=C)[C@@H]4[C@@H]3CCC2=C1 JMCNUPJJRLUBQN-MQODNCJTSA-N 0.000 claims 1
SWTFCHBLELBDJW-CKRDVPRESA-N C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=C)CC=C4[C@@]3(C=CC(=C4)C5=CC=CC=C5C(=O)O)C Chemical compound C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=C)CC=C4[C@@]3(C=CC(=C4)C5=CC=CC=C5C(=O)O)C SWTFCHBLELBDJW-CKRDVPRESA-N 0.000 claims 1
239000003883 ointment base Substances 0.000 claims 1
239000003446 ligand Substances 0.000 abstract description 24
238000000034 method Methods 0.000 abstract description 24
241000282414 Homo sapiens Species 0.000 abstract description 18
239000003620 semiochemical Substances 0.000 abstract description 12
210000001121 vomeronasal organ Anatomy 0.000 description 78
230000000694 effects Effects 0.000 description 45
230000004044 response Effects 0.000 description 36
102000005962 receptors Human genes 0.000 description 32
108020003175 receptors Proteins 0.000 description 32
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
239000000126 substance Substances 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
210000001706 olfactory mucosa Anatomy 0.000 description 23
230000000638 stimulation Effects 0.000 description 22
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
238000003786 synthesis reaction Methods 0.000 description 21
208000019901 Anxiety disease Diseases 0.000 description 17
230000006870 function Effects 0.000 description 17
239000003016 pheromone Substances 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 16
210000003016 hypothalamus Anatomy 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
230000036651 mood Effects 0.000 description 15
239000000243 solution Substances 0.000 description 15
QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 14
230000036506 anxiety Effects 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
230000009471 action Effects 0.000 description 11
239000003814 drug Substances 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 10
238000012360 testing method Methods 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
229940049706 benzodiazepine Drugs 0.000 description 9
230000000723 chemosensory effect Effects 0.000 description 9
230000002996 emotional effect Effects 0.000 description 9
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
150000001557 benzodiazepines Chemical class 0.000 description 8
229940079593 drug Drugs 0.000 description 8
206010036618 Premenstrual syndrome Diseases 0.000 description 7
239000013543 active substance Substances 0.000 description 7
230000006399 behavior Effects 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
108091008690 chemoreceptors Proteins 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
201000000484 premenstrual tension Diseases 0.000 description 7
239000000047 product Substances 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
241000282412 Homo Species 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
229920006362 Teflon® Polymers 0.000 description 6
239000000443 aerosol Substances 0.000 description 6
238000000540 analysis of variance Methods 0.000 description 6
NXQOQNROJJFYCJ-FZFXZXLVSA-N androst-16-ene Chemical class C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC21 NXQOQNROJJFYCJ-FZFXZXLVSA-N 0.000 description 6
239000002249 anxiolytic agent Substances 0.000 description 6
230000003542 behavioural effect Effects 0.000 description 6
229960002495 buspirone Drugs 0.000 description 6
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
239000003380 propellant Substances 0.000 description 6
241000894007 species Species 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
101150041968 CDC13 gene Proteins 0.000 description 5
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
230000000949 anxiolytic effect Effects 0.000 description 5
230000002567 autonomic effect Effects 0.000 description 5
230000009910 autonomic response Effects 0.000 description 5
229960005233 cineole Drugs 0.000 description 5
230000001054 cortical effect Effects 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000000857 drug effect Effects 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000002674 ointment Substances 0.000 description 5
208000020016 psychiatric disease Diseases 0.000 description 5
230000028327 secretion Effects 0.000 description 5
231100000430 skin reaction Toxicity 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
229960003604 testosterone Drugs 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
KRVXMNNRSSQZJP-PHFHYRSDSA-N 5alpha-androst-16-en-3alpha-ol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21 KRVXMNNRSSQZJP-PHFHYRSDSA-N 0.000 description 4
108050002069 Olfactory receptors Proteins 0.000 description 4
102000012547 Olfactory receptors Human genes 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
150000001441 androstanes Chemical class 0.000 description 4
210000003403 autonomic nervous system Anatomy 0.000 description 4
230000027455 binding Effects 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000003928 nasal cavity Anatomy 0.000 description 4
210000005036 nerve Anatomy 0.000 description 4
210000000461 neuroepithelial cell Anatomy 0.000 description 4
210000001331 nose Anatomy 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000035479 physiological effects, processes and functions Effects 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000036387 respiratory rate Effects 0.000 description 4
230000035807 sensation Effects 0.000 description 4
235000019615 sensations Nutrition 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000007858 starting material Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
VQLZQUQRKKUURJ-HVTWWXFQSA-N (8s,9s,10r,13r,14s)-3-methoxy-10,13-dimethyl-2,7,8,9,11,12,14,15-octahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1C[C@@H]2[C@](CCC(OC)=C3)(C)C3=CC[C@H]2[C@@H]2CC=C[C@]21C VQLZQUQRKKUURJ-HVTWWXFQSA-N 0.000 description 3
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
206010029216 Nervousness Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
150000001443 androstenes Chemical class 0.000 description 3
210000003050 axon Anatomy 0.000 description 3
239000012267 brine Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229930007050 cineol Natural products 0.000 description 3
238000004891 communication Methods 0.000 description 3
239000012043 crude product Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000011835 investigation Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000028161 membrane depolarization Effects 0.000 description 3
CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
230000001722 neurochemical effect Effects 0.000 description 3
208000015238 neurotic disease Diseases 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
230000001624 sedative effect Effects 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
239000004332 silver Substances 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000000946 synaptic effect Effects 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
CRMOMCHYBNOFIV-UHFFFAOYSA-N 1,3,5(10),16-estratetraen-3-ol Natural products OC1=CC=C2C3CCC(C)(C=CC4)C4C3CCC2=C1 CRMOMCHYBNOFIV-UHFFFAOYSA-N 0.000 description 2
CRMOMCHYBNOFIV-BDXSIMOUSA-N 16-estratetraen-3-ol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC2=C1 CRMOMCHYBNOFIV-BDXSIMOUSA-N 0.000 description 2
HFVMLYAGWXSTQI-QYXZOKGRSA-N 5alpha-androst-16-en-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21 HFVMLYAGWXSTQI-QYXZOKGRSA-N 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
206010052804 Drug tolerance Diseases 0.000 description 2
241001539473 Euphoria Species 0.000 description 2
206010015535 Euphoric mood Diseases 0.000 description 2
208000011688 Generalised anxiety disease Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
239000003810 Jones reagent Substances 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
208000019022 Mood disease Diseases 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
108010002724 Pheromone Receptors Proteins 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
206010039897 Sedation Diseases 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 2
102100020993 Zinc finger protein ZFPM1 Human genes 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000016571 aggressive behavior Effects 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
229940005530 anxiolytics Drugs 0.000 description 2
QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
230000003925 brain function Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 2
239000006071 cream Substances 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
208000024732 dysthymic disease Diseases 0.000 description 2
230000008451 emotion Effects 0.000 description 2
150000002165 estrenes Chemical class 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000000763 evoking effect Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000003205 fragrance Substances 0.000 description 2
208000029364 generalized anxiety disease Diseases 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000026781 habituation Effects 0.000 description 2
235000003642 hunger Nutrition 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
210000000492 nasalseptum Anatomy 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
239000002304 perfume Substances 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000002427 pheromone receptor Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
238000012746 preparative thin layer chromatography Methods 0.000 description 2
230000003304 psychophysiological effect Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
230000011514 reflex Effects 0.000 description 2
210000001533 respiratory mucosa Anatomy 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000036280 sedation Effects 0.000 description 2
239000000932 sedative agent Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000002265 sensory receptor cell Anatomy 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
230000008054 signal transmission Effects 0.000 description 2
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
239000000021 stimulant Substances 0.000 description 2
210000000225 synapse Anatomy 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
UWHAKIWRMWFVJG-VEYLTJTESA-N (3R,5S,8R,9S,10S,13R,14S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21.C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC[C@H]21 UWHAKIWRMWFVJG-VEYLTJTESA-N 0.000 description 1
MUMGGOZAMZWBJJ-XZIMXZIZSA-N (8r,9s,10r,13s,14s)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-XZIMXZIZSA-N 0.000 description 1
PYOOIFRHHPZHHQ-QHGFLKOESA-N (8s,9s,10r,13r,14s)-10,13,17-trimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical class C1CC2=CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC(C)[C@@]1(C)CC2 PYOOIFRHHPZHHQ-QHGFLKOESA-N 0.000 description 1
FCTXXUCLEYKQFF-VMXHOPILSA-N (8s,9s,10r,13r,14s)-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CC=C21 FCTXXUCLEYKQFF-VMXHOPILSA-N 0.000 description 1
CBSGPWTYXRWZHA-VDWQKOAOSA-N (8s,9s,10r,13s,14s)-6,10,13-trimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C=C1C(C)=C[C@@H]1[C@@H]2CC[C@]2(C)CCC[C@H]21 CBSGPWTYXRWZHA-VDWQKOAOSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
VBXVNLLGCLHXDG-XWSJACJDSA-N 17-Methyl-18-norandrosta-4,13(17)-dien-3-one Chemical group O=C1CC[C@]2(C)[C@H]3CCC4=C(C)CC[C@H]4[C@@H]3CCC2=C1 VBXVNLLGCLHXDG-XWSJACJDSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
HDBRXSVHQAGDAZ-YRXWBPOGSA-N 3-Methoxyestra-1,3,5(10),16-tetraene Chemical compound C1C[C@]2(C)C=CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 HDBRXSVHQAGDAZ-YRXWBPOGSA-N 0.000 description 1
ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
ANHKKFTYQZQBGR-SQXVBZLISA-N C[C@@]12C=CC=C1[C@@H]1CC[C@H]3C[C@@H](CC[C@]3(C)[C@H]1CC2)O Chemical compound C[C@@]12C=CC=C1[C@@H]1CC[C@H]3C[C@@H](CC[C@]3(C)[C@H]1CC2)O ANHKKFTYQZQBGR-SQXVBZLISA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010010219 Compulsions Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
206010012374 Depressed mood Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
206010013954 Dysphoria Diseases 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
206010016275 Fear Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010051602 Laziness Diseases 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010029333 Neurosis Diseases 0.000 description 1
206010029897 Obsessive thoughts Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
241000135309 Processus Species 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
241000270295 Serpentes Species 0.000 description 1
229910021607 Silver chloride Inorganic materials 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
206010065954 Stubbornness Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
235000016639 Syzygium aromaticum Nutrition 0.000 description 1
244000223014 Syzygium aromaticum Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108091005722 Vomeronasal receptors Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
101710163895 Zinc finger protein ZFPM1 Proteins 0.000 description 1
HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000029650 alcohol withdrawal Diseases 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000000538 analytical sample Substances 0.000 description 1
150000001428 androst-16-enes Chemical class 0.000 description 1
229940061641 androsterone Drugs 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000049 anti-anxiety effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
230000037007 arousal Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
238000013542 behavioral therapy Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
KRVXMNNRSSQZJP-UHFFFAOYSA-N beta-androstenol Natural products C1C(O)CCC2(C)C3CCC(C)(C=CC4)C4C3CCC21 KRVXMNNRSSQZJP-UHFFFAOYSA-N 0.000 description 1
230000002902 bimodal effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001273 butane Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
208000012839 conversion disease Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
150000001907 coumarones Chemical class 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000000624 ear auricle Anatomy 0.000 description 1
238000000537 electroencephalography Methods 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
HJKVPZJVBHWFCQ-BDXSIMOUSA-N estra-1,3,5(10)-trien-3-ol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 HJKVPZJVBHWFCQ-BDXSIMOUSA-N 0.000 description 1
GRXPVLPQNMUNNX-MHJRRCNVSA-N estrane Chemical compound C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 GRXPVLPQNMUNNX-MHJRRCNVSA-N 0.000 description 1
230000012173 estrus Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
FIMAYKDZLLQUDW-UHFFFAOYSA-N fluoro(dioxido)borane;trimethyloxidanium Chemical compound C[O+](C)C.C[O+](C)C.[O-]B([O-])F FIMAYKDZLLQUDW-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
150000008134 glucuronides Chemical group 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
239000000545 human pheromone Substances 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007758 mating behavior Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
MBXNQZHITVCSLJ-UHFFFAOYSA-N methyl fluorosulfonate Chemical compound COS(F)(=O)=O MBXNQZHITVCSLJ-UHFFFAOYSA-N 0.000 description 1
229960001566 methyltestosterone Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000002969 morbid Effects 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
230000004973 motor coordination Effects 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
230000007433 nerve pathway Effects 0.000 description 1
230000003767 neural control Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
208000025319 neurotic depression Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000929 nociceptor Anatomy 0.000 description 1
108091008700 nociceptors Proteins 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
230000009965 odorless effect Effects 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000002889 oleic acids Chemical class 0.000 description 1
210000003977 optic chiasm Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
230000036407 pain Effects 0.000 description 1
210000003254 palate Anatomy 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001451 polypropylene glycol Chemical class 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960002847 prasterone Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000001294 propane Substances 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
230000004800 psychological effect Effects 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
210000003370 receptor cell Anatomy 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000010539 reproductive behavior Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
230000009329 sexual behaviour Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000035941 sexual motivation Effects 0.000 description 1
229920005573 silicon-containing polymer Polymers 0.000 description 1
HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
229910001923 silver oxide Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229960004249 sodium acetate Drugs 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000001256 steam distillation Methods 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
125000002345 steroid group Chemical class 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
210000001779 taste bud Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000001149 thermolysis Methods 0.000 description 1
239000012749 thinning agent Substances 0.000 description 1
210000000211 third ventricle Anatomy 0.000 description 1
238000012549 training Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
210000002983 tuber cinereum Anatomy 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
210000001614 vomer Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NO955085A 1993-06-15 1995-12-14 Farmasøytisk blanding egnet for nasal administrering, forbindelse og anvendelse derav NO309926B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7735993A	1993-06-15	1993-06-15
PCT/US1993/009349 WO1994028904A1 (en)	1993-06-15	1993-09-28	Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods

Publications (3)

Publication Number	Publication Date
NO955085D0 NO955085D0 (no)	1995-12-14
NO955085L NO955085L (no)	1996-02-14
NO309926B1 true NO309926B1 (no)	2001-04-23

Family

ID=22137596

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO955085A NO309926B1 (no)	1993-06-15	1995-12-14	Farmasøytisk blanding egnet for nasal administrering, forbindelse og anvendelse derav

Country Status (14)

Country	Link
EP (2)	EP0711169B1 (ja)
JP (1)	JP3705806B2 (ja)
AT (1)	ATE255898T1 (ja)
BG (1)	BG63452B1 (ja)
BR (1)	BR9307867A (ja)
CA (1)	CA2165325A1 (ja)
DE (1)	DE69333352T2 (ja)
ES (1)	ES2210243T3 (ja)
FI (1)	FI956029A (ja)
HU (1)	HUT74172A (ja)
NO (1)	NO309926B1 (ja)
NZ (1)	NZ257218A (ja)
PL (1)	PL183582B1 (ja)
WO (1)	WO1994028904A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5883087A (en) *	1991-01-07	1999-03-16	Pherin Corporation	Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5969168A (en) *	1991-01-07	1999-10-19	Pherin Corporation	Androstanes for inducing hypothalamic effects
US5994333A (en) *	1994-08-04	1999-11-30	Pherin Corporation	Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5563131A (en) *	1994-08-04	1996-10-08	Pherin Corporation	Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6066627A (en) *	1994-08-04	2000-05-23	Pherin Corporation	Steroids as neurochemical initiators of change in human blood levels of LH
DE69634134D1 (de) *	1995-10-19	2005-02-03	Univ Columbia	Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
US5922699A (en) *	1996-06-07	1999-07-13	Pherin Corporation	19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
ES2273374T3 (es) *	1996-07-23	2007-05-01	Pherin Pharmaceuticals, Inc.	Esteroides como estimuladores neuroquimicos del ovn para aliviar los sintomas de pms.
US6093389A (en) *	1997-12-01	2000-07-25	American Cyanamid Company	Methods and compositions for attracting and controlling termites
US6544971B1 (en) *	2000-02-04	2003-04-08	Pherin Pharmaceuticals, Inc.	Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices
US6919337B2 (en)	2000-04-07	2005-07-19	Novartis, Ag	8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US7019136B2 (en)	2000-04-07	2006-03-28	Novartis, Ag	8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
JP3705546B2 (ja) *	2000-07-05	2005-10-12	松下電器産業株式会社	嗅粘膜刺激性化合物スクリーニング装置及び方法
US10322138B2 (en)	2012-12-28	2019-06-18	Pherin Pharmaceuticals, Inc.	Treatment of depressive disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB765509A (en) *	1954-02-04	1957-01-09	Pfizer & Co C	Improvements in or relating to steroids and the preparation thereof
GB1175219A (en) *	1967-06-22	1969-12-23	Ici Ltd	3-Aminoalkoxycarbonylmethylene Steroid Derivatives
GB1267514A (en) *	1968-07-23	1972-03-22	Nat Res Dev	Improvements relating to artificial insemination of pigs
DE2345376A1 (de) *	1973-09-06	1975-03-20	Schering Ag	Pharmazeutische zubereitung ii
GB1550343A (en) *	1975-07-16	1979-08-15	Gist Brocades Nv	Androstane derivatives
DE2758549A1 (de) *	1977-12-23	1979-07-05	Schering Ag	Pharmazeutische zubereitung
US5155045A (en) *	1985-01-25	1992-10-13	Trustees Of The University Of Penn.	Use of male essence to alter female endocrine response
DD251077A1 (de) *	1986-07-21	1987-11-04	Adw Ddr	Mittel zur anregung der brunstreaktion bei schweinen
US5208227A (en) *	1987-08-25	1993-05-04	University Of Southern California	Method, compositions, and compounds for modulating brain excitability
US5232917A (en) *	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
FR2622194B1 (fr) *	1987-10-27	1990-03-23	Theramex Laboratoire	Nouveaux derives de la 19-nor progesterone, leur procede d'obtention et les compositions pharmaceutiques en contenant
US5969168A (en) *	1991-01-07	1999-10-19	Pherin Corporation	Androstanes for inducing hypothalamic effects
CA2425841C (en) *	1991-11-22	2006-01-10	Alcon Laboratories, Inc.	Angiostatic steroids
US5272134A (en) *	1992-03-24	1993-12-21	Erox Corporation	Fragrance compositions and other compositions which contain human pheromones

1993
- 1993-09-28 DE DE69333352T patent/DE69333352T2/de not_active Expired - Lifetime
- 1993-09-28 EP EP93923753A patent/EP0711169B1/en not_active Expired - Lifetime
- 1993-09-28 BR BR9307867A patent/BR9307867A/pt not_active Application Discontinuation
- 1993-09-28 EP EP03076439A patent/EP1340502A3/en not_active Withdrawn
- 1993-09-28 CA CA002165325A patent/CA2165325A1/en not_active Abandoned
- 1993-09-28 PL PL93312279A patent/PL183582B1/pl unknown
- 1993-09-28 HU HU9503578A patent/HUT74172A/hu unknown
- 1993-09-28 NZ NZ257218A patent/NZ257218A/en unknown
- 1993-09-28 ES ES93923753T patent/ES2210243T3/es not_active Expired - Lifetime
- 1993-09-28 AT AT93923753T patent/ATE255898T1/de not_active IP Right Cessation
- 1993-09-28 WO PCT/US1993/009349 patent/WO1994028904A1/en active IP Right Grant
- 1993-09-28 JP JP50171195A patent/JP3705806B2/ja not_active Expired - Fee Related
1995
- 1995-12-14 FI FI956029A patent/FI956029A/fi unknown
- 1995-12-14 NO NO955085A patent/NO309926B1/no not_active IP Right Cessation
1996
- 1996-01-15 BG BG100286A patent/BG63452B1/bg unknown

Also Published As

Publication number	Publication date
BR9307867A (pt)	1996-07-30
EP1340502A2 (en)	2003-09-03
ATE255898T1 (de)	2003-12-15
HUT74172A (en)	1996-11-28
EP1340502A3 (en)	2004-01-21
FI956029A (fi)	1996-02-14
BG100286A (bg)	1997-02-28
JP3705806B2 (ja)	2005-10-12
JPH09501409A (ja)	1997-02-10
NZ257218A (en)	1998-07-28
PL183582B1 (pl)	2002-06-28
EP0711169A4 (en)	2000-05-31
NO955085L (no)	1996-02-14
BG63452B1 (bg)	2002-02-28
HU9503578D0 (en)	1996-02-28
CA2165325A1 (en)	1994-12-22
DE69333352T2 (de)	2004-07-22
PL312279A1 (en)	1996-04-15
NO955085D0 (no)	1995-12-14
EP0711169A1 (en)	1996-05-15
AU5350494A (en)	1995-01-03
FI956029A0 (fi)	1995-12-14
EP0711169B1 (en)	2003-12-10
WO1994028904A1 (en)	1994-12-22
DE69333352D1 (de)	2004-01-22
ES2210243T3 (es)	2004-07-01
AU691474B2 (en)	1998-05-21

Legal Events

Date	Code	Title	Description
2003-05-05	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN MARCH 2003

Publication	Publication Date	Title
NO309926B1 (no)	2001-04-23	Farmasøytisk blanding egnet for nasal administrering, forbindelse og anvendelse derav
US5883087A (en)	1999-03-16	Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
EP0715517B1 (en)	2003-11-05	Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions
RU2160740C2 (ru)	2000-12-20	Андростаны
WO1997036596A1 (en)	1997-10-09	Steroids as neurochemical initiators of change in human blood levels of lh or fsh
MXPA97002252A (en)	1997-06-01	New androstans to induce efectoshipotalami
EP0924219A2 (en)	1999-06-23	Novel estrenes for inducing hypothalamic effects
US6352980B1 (en)	2002-03-05	Estrenes for inducting hypothalamic effects
US5783571A (en)	1998-07-21	Method of altering hypothalamic function by nasal administration of estrene steroids
US6140316A (en)	2000-10-31	Estrene steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions
AU691474C (en)	2000-01-20	Androstane steroids as neurochemical initiators of change inhuman hypothalamic function and related pharmaceutical compositions and methods
US20020103391A1 (en)	2002-08-01	Novel androstanes for inducing hypothalamic effects
US20020143001A1 (en)	2002-10-03	Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
NZ330376A (en)	1999-09-29	Androstane steroid ligands as neurochemical initiators of change in human hypothalamic and autonomic function
NZ330570A (en)	2000-06-23	the use of estrene steroids as neurochemical initiators of change in human hypothalamic funtion